Pacer Advisors Inc. Has $5 Million Position in GlaxoSmithKline plc (NYSE:GSK)

Pacer Advisors Inc. raised its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 4.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 117,244 shares of the pharmaceutical company’s stock after buying an additional 5,500 shares during the period. Pacer Advisors Inc.’s holdings in GlaxoSmithKline were worth $5,004,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of GSK. Renaissance Technologies LLC raised its holdings in shares of GlaxoSmithKline by 6.9% during the 2nd quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock valued at $610,776,000 after purchasing an additional 989,181 shares in the last quarter. Morgan Stanley raised its holdings in shares of GlaxoSmithKline by 5.8% during the 2nd quarter. Morgan Stanley now owns 3,845,882 shares of the pharmaceutical company’s stock valued at $153,912,000 after purchasing an additional 212,166 shares in the last quarter. Eaton Vance Management raised its holdings in shares of GlaxoSmithKline by 6.8% during the 2nd quarter. Eaton Vance Management now owns 2,229,470 shares of the pharmaceutical company’s stock valued at $89,034,000 after purchasing an additional 141,256 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of GlaxoSmithKline by 7,574.0% during the 2nd quarter. Jane Street Group LLC now owns 1,816,424 shares of the pharmaceutical company’s stock valued at $72,693,000 after purchasing an additional 1,792,754 shares in the last quarter. Finally, Kahn Brothers Group Inc. DE raised its holdings in shares of GlaxoSmithKline by 25.7% during the 2nd quarter. Kahn Brothers Group Inc. DE now owns 1,605,014 shares of the pharmaceutical company’s stock valued at $64,233,000 after purchasing an additional 328,464 shares in the last quarter. 11.12% of the stock is owned by institutional investors.

Several research analysts recently commented on the stock. Societe Generale upgraded shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a report on Tuesday, September 3rd. ValuEngine downgraded shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Cantor Fitzgerald upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, August 13th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a report on Monday, June 17th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $41.79.

In related news, Director Plc Glaxosmithkline acquired 177,777 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were bought at an average cost of $45.00 per share, with a total value of $7,999,965.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is owned by corporate insiders.

Shares of GSK opened at $42.18 on Friday. The company has a market capitalization of $105.21 billion, a PE ratio of 13.35, a price-to-earnings-growth ratio of 2.02 and a beta of 0.68. GlaxoSmithKline plc has a one year low of $36.41 and a one year high of $43.22. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48. The company’s fifty day moving average price is $41.67 and its 200 day moving average price is $40.77.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The company had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $9.55 billion. Analysts anticipate that GlaxoSmithKline plc will post 2.96 earnings per share for the current year.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Most Active Stocks

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.